ClinicalTrials.gg
RecruitingNCT06833320Updated Nov 18, 2026

Propranolol Treatment for Postoperative Chylothorax

A Phase 1/2 interventional study of Propranolol Hydrochloride and Placebo in Postoperative Chylothorax, Congenital Heart Disease and Open Heart Surgery, sponsored by June Wu. Recruiting at 1 site in United States. Open to participants aged 7 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by June Wu · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
7 Days to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Planned enrollment
86th of 184
50 · median 48
Started
2025
with 12 others
Phase 1/2
8 of 356
2 open now
Primary completion
2028-09
later than 63 of 86 live
Registered
334th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 86th largest by planned enrollment of the 184 interventional ones that give a count, is one of 13 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 63 of the 86 other live ones, and was the 334th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 7 Days to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patients, and after open heart surgery, the fluid shifts that occur overwhelms these abnormal lung lymphatics. As a result, postoperative chylothorax occurs. Propranolol has been found to be helpful in resolving postoperative chylothorax very quickly (9 days) in a subset of postoperative chylothorax patients (60%). However, it is not known why some patients respond and some do not. The investigators hypothesize that propranolol is safe to use in this patient population, and that certain clinical factors will predict propranolol response, but more importantly, some clinical factors can be optimize to allow more patients with postoperative chylothorax to respond to and benefit from propranolol. In order to improve the understanding of how propranolol works and to maximize benefit to patients, the investigators propose to perform a prospective, randomized, double-blind clinical trial to learn how to best use propranolol in patients with postoperative chylothorax.

Read the detailed description

This clinical trial will prospectively enroll eligible patients and randomize them to placebo or propranolol (1:1). This study will aim to enroll 50 patients, randomized to 25 placebo and 25 propranolol treatment. After patients have been consented, registered, and screened, they will be entered into the study. Participants will be randomized to placebo or propranolol in a 1:1 ratio. Randomization will be double-blinded, and each enrolled participant will be given a number and receive coded medication from the research pharmacy. Patients may undergo a screening MR lymphangiogram (MRL) prior to starting treatment. The criteria for an MRL will require that no additional sedation be given, and patient or parent/legal guardian consents to an MRL. Thus, only patients who are already sedated, or who will be able to undergo the MRL without sedation, and who opts in to the MRL will be eligible. Propranolol or placebo will be administered for 9 days after reaching the lowest effective goal dose not to exceed 2mg/kg/day, or maximum tolerated dose, after which the study groups will be unmasked.

Participants who have ≥80% reduction in volume of chylothorax drainage after 9 days of treatment and who received propranolol are identified as "responders". They will be taken off the study officially at this point as no more study interventions will be given. They will be tapered off of propranolol gradually as clinically indicated.

Participants who have ≥80% reduction in volume of chylothorax drainage but who received placebo will be the "natural history cohort". This will serve to demonstrate, as baseline, the percentage of participants who naturally resolve their chylothorax without intervention.

Patients who have \<80% reduction in chylothorax drainage and who received propranolol, will be categorized as initial "non-responders". They will be officially taken off the study.

Participants who have \<80% reduction in chylothorax drainage and who received placebo are considered a control group. They will be given propranolol for 9 days as a single-arm, open study and re-evaluated after a 9-day treatment. After 9 days at goal dosing, they will receive the same treatment as the responders and non-responders in the propranolol-treated group.

03

Conditions studied

  • Postoperative Chylothorax
  • Congenital Heart Disease
  • Open Heart Surgery
  • Chylothorax
04

Who can participate

Ages eligible
7 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥7 days and ≤18 years old at time of original cardiac surgery
  • Congenital structural cardiac anomaly necessitating surgical correction. Examples include but are not limited to: ASD, VSD, single ventricles, HLHS, Tetralogy of Fallot, transposition of great vessels, AV canal, heart transplant
  • developed high output postoperative chylothorax (≥10mL/kg/day), or
  • persistent chylous drainage at any volume for ≥7 days after open heart surgery for a congenital cardiac defect
  • ≥70% lymphocytes, or
  • pleural triglyeride (TG) ≥ half of serum TG, or chylomicron positive

    • for patients with lower than normal serum lymphocyte count (agedependent), ≥60% lymphocytes in pleural fluids
  • Must have measurable output (chylothorax output in mL)
  • Any level of respiratory support (room air, supplemental oxygen, CPAP/BIPAP, ventilatory support)
  • Any level of inpatient support (ICUs, step-down units, floor)
  • Study participants can be on concomitant treatment for postoperative chylothorax started prior to study initiation
  • Study participants can continue on on-going treatment for their primary cardiac other medical conditions
  • Study participants can initiate new treatments for their primary cardiac or other medical conditions during trial period
  • Adequate renal function
  • Not on dialysis
  • No hemodynamically unstable bradycardia
  • No systolic hypotension not corrected by pressor support
  • Not in 2nd or 3rd degree heart block
  • No history of asthma
  • A parent or a legal guardian must sign a written and HIPAA Form
  • Patients will be required to also be enrolled in a related study (AAAQ6902) which collects chylothorax fluid for cell isolation and genetic analysis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Renal failure at time of enrollment
  • Hypotension despite pressor support
  • Unstable bradycardia without capacity for pacing
  • History of asthma or chronic bronchodilator therapy
  • Uncontrolled hypoglycemia or hyperglycemia as per investigators' judgment
  • Study participant will be removed from study if they failed 2 consecutive attempts to initiate propranolol (>10% drop in BP/HR from age-adjusted normative range)
  • Study participant experiences ≥ Grade 3 AE (SAE)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo suspension will only have Ora-Blend

    Drug: Placebo

  • Active comparator
    Propranolol hydrochloride

    Subjects will be randomized to receive 2mg/kg/day. Propranolol will be administered orally, either as a tablet or as a solution, in equal divided doses three times a day.

    Drug: Propranolol Hydrochloride

Interventions

  • DrugPropranololStudies of PropranololPropranolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.

    Also known as: Propranolol, 2-Propanol, 1-[(1-methylethyl)amino]-3-(1- naphthalenyloxy)-, hydrochloride

  • DrugPlacebo

    Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle

    Also known as: Ora-Blend

06

What researchers measure

Primary outcomes

  1. Daily heart rates recorded in flow chart and 1 hour after each dose

    Safety outcome

    Time frame: 24 days

  2. Daily blood pressures recorded in flow chart and 1 hour after each dose

    Safety outcome

    Time frame: 24 days

  3. Daily glucose levels

    Safety outcome

    Time frame: 24 days

  4. Expected and unexpected AEs, per patient

    Safety outcome

    Time frame: 24 days

  5. Days with documented chest tube (# days), CXR

    Will also measure the daily output (volume) in the chest tube(s)

    Time frame: 24 days

  6. Initial volume of fluid drained (mL, mL/kg/day)

    The volume at the initial day of postoperative chylothorax diagnosis

    Time frame: Day 0

  7. Days hospitalized

    The length of hospital stay, from post-surgery to discharge

    Time frame: 6 months

Secondary outcomes

  1. Thyroglobulin (TG) lymphocyte count

    The TG count will be analyzed from the postoperative chylothorax fluid.

    Time frame: 24 days

  2. Pre-operative and post-operative echocardiogram anatomic findings for patients with 4-chamber hearts

    This outcome will be reported as the percent of patients with normal LV function, normal RV function, and normal pulmonary artery pressure.

    Time frame: Pre-operative and up to 24 days

  3. Pre-operative and post-operative echocardiogram anatomic findings for patients with single ventricle (SV) physiology

    This outcome will be reported as the percent of patients with normal ventricular function and normal pulmonary artery pressure.

    Time frame: Pre-operative and up to 24 days

  4. Percent of patients with Type 1 anatomy

    Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype

    Time frame: Day 0

  5. Percent of patients with Type 2 anatomy

    Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype

    Time frame: Day 0

  6. Percent of patients with Type 3 anatomy

    Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype

    Time frame: Day 0

  7. Percent of patients with Type 4 anatomy

    Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype

    Time frame: Day 0

  8. Serum albumin

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  9. White Blood Cell (WBC) count

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  10. C-Reactive Protein (CRP)

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  11. Immunoglobulin level

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  12. AT3 titer

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  13. Protein S titer

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  14. Protein C titer

    to be extracted from clinical lab results, if available

    Time frame: 24 days

  15. Hours on bypass during CHD surgery

    The amount of time the participant was on bypass during heart surgery

    Time frame: During surgery

  16. Triglyceride level in chylothorax fluid

    Triglyceride levels will be measured

    Time frame: 24 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Feb 18, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Jan 1, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Nov 18, 2026
Sites
Columbia University Irving Medical Center/NewYork-Presbyterian is now Recruiting
Nov 18, 2026
Contact
Study contact now listed: added j•••@cumc.columbia.edu · •••3704. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    Columbia University Irving Medical Center/NewYork-Presbyterian is now Recruiting
    Contact Study contact now listed: added j•••@cumc.columbia.edu · •••3704. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06833320
Lead sponsor
June Wu
Collaborators
United States Department of Defense
Responsible party
June Wu (Associate Professor of Surgery, Columbia University) — Sponsor-investigator
First posted
Feb 18, 2025
Start date
Sep 9, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

June Wu, MD
Contact
jw92@cumc.columbia.edu
212-342-3704
June Wu, MD
principal investigator · Columbia University Irving Medical Center/ New York Presbyterian hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propranolol

Start the discussion